Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Br J Haematol. 2014 Apr 2;166(2):177–188. doi: 10.1111/bjh.12867

Figure 2. Ibrutinib inhibits cell growth and proliferation and reduces the percentage of cells in S-phase in a dose-dependent manner.

Figure 2

(A) Cell growth curves for untreated HCL cell lines ESKOL (left) and HC-1 (right), indicated as the control, and treated with ibrutinib (0.5 μM, 1 μM or 5 μM); at the indicated time points, cells were counted by flow cytometry, the graphs represent the mean and SEM, as indicated by the lines and error bars with ** as p<0.01 (n=3). (B) Left-hand graph depicts the effect of ibrutinib on the proliferation of HCL cell lines, ESKOL (black bars) and HC-1 (grey bars), using dose escalation, as assessed by XTT assay after 72 h of incubation., bar diagrams represent the mean ± SEM of 3 independent experiments with ** as p<0.01. The right-hand graph shows the percentage of cell cycle phase distribution, assessed by BrdU and 7-AAD incorporation, in the HC-1 cell line after 48 h of incubation with ibrutinib (0.5 μM, 1 μM or 5 μM), untreated cells are indicated as a control. The bars represent the mean of the percentage of cells in G0/G1 (lighter grey) S-phase (grey) and G2/M (darker grey) (n=3).